Company Analysis
Sign in

Veraxa Biotech AG (VRXA)

Nasdaq: VRXA · Pharmaceutical Preparations · filing with the SEC since 2025
Full chart Alerts Compare
Grade5.3
◀ Past 6.0● Present 5.1▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202647
Newest filingOct 29 · 4
Annual reportJun 16, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$100,000
Patents grantedn/a
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.

News

Oct 29, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 4, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Sep 4, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Aug 31, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 31, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton VRXA · research, not advice